[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Dong-A University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":45},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":5},"100420486","phase-4-ticagrelor-de-escalation-strategy-in-ami-patients-100420486",false,"NCT04755387","Ticagrelor De-escalation Strategy in AMI Patients","EASTYLE (DE-escAlation Strategy for Optimal Ticagrelor Therapy in Acute MYocardiaL Infarction PatiEnts, Prospective, Multicenter, Randomized) Trial","Inclusion Criteria:\n\n* Diagnosis with acute myocardial infarction.\n* Age ≥19 year-old\n* Successful PCI with ultrathin bioresorbable polymer sirolimus-eluting stents (Orsiro; Biotronik AG).\n* Provision of informed consent.\n\nExclusion Criteria:\n\n* Any prior event of hemorrhagic stroke or ICH.\n* Active bleeding (e.g., GI bleeding, ICH) or high-risk of serious bleeding.\n* Bleeding diathesis or coagulopathy (e.g., hemoglobin ≤ 10 g\u002FdL or platelet count \\\u003C 100,000\u002FμL, bleeding needing transfusion within 30 days, and so on).\n* Allergy to stent metal, contrat media, and antiplatelet regimens.\n* Moderate to severe hepatic dysfunction (Child-Pugh class B or C).\n* Need for oral anticoagulation therapy.\n* Current or potential pregnancy.\n* Currently treated with strong CYP3A4 inhibitors.\n* Life expectancy \\\u003C1 year.","ALL","19 Years","80 Years",{"count":20,"type":21},2312,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","DAPT de-escalation strategies to reduce bleeding include de-escalation of DAPT intensity (downgrading from potent P2Y12 inhibitor at conventional doses to either clopidogrel or reduced-dose prasugrel) or abbreviation of DAPT duration. The EASTYLE trial will evaluate a hybrid DAPT de-escalation strategy (reduced-dose ticagrelor, followed by aspirin early discontinuation) in AMI patients, compared with a conventional DAPT strategy.",[27],"Acute Myocardial Infarction",[29,30,31,32],"Ticagrelor","DAPT","De-escalation strategy","Abbreviated strategy","RECRUITING","2025-09-26",{"date":36,"type":37},"2025-10-01","ACTUAL",{"date":39,"type":37},"2023-03-27",{"date":41,"type":21},"2028-01-31",{"name":43,"class":44},"Dong-A University","OTHER",""]